Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment

NCT01949545 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Hematologic Malignancies
Hepatic Impairment

Interventions

DRUG: Carfilzomib

Sponsor

Amgen